Trial Profile
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications Acquired immunodeficiency syndrome
- Focus Pharmacokinetics
- Sponsors Elea
- 11 Apr 2016 New trial record
- 06 Apr 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 06 Apr 2016 Primary endpoint (Area Under the Curve [AUC]) has been met, as per the results published in the International Journal of Clinical Pharmacology and Therapeutics